These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Activity of dalbavancin against Bacillus anthracis in vitro and in a mouse inhalation anthrax model. Heine HS; Purcell BK; Bassett J; Miller L; Goldstein BP Antimicrob Agents Chemother; 2010 Mar; 54(3):991-6. PubMed ID: 20047912 [TBL] [Abstract][Full Text] [Related]
4. Efficacy of oritavancin in a murine model of Bacillus anthracis spore inhalation anthrax. Heine HS; Bassett J; Miller L; Bassett A; Ivins BE; Lehoux D; Arhin FF; Parr TR; Moeck G Antimicrob Agents Chemother; 2008 Sep; 52(9):3350-7. PubMed ID: 18606841 [TBL] [Abstract][Full Text] [Related]
5. Hollow-fiber pharmacodynamic studies and mathematical modeling to predict the efficacy of amoxicillin for anthrax postexposure prophylaxis in pregnant women and children. Louie A; Vanscoy B; Liu W; Kulawy R; Drusano GL Antimicrob Agents Chemother; 2013 Dec; 57(12):5946-60. PubMed ID: 24041894 [TBL] [Abstract][Full Text] [Related]
6. The Fluorocycline TP-271 Is Efficacious in Models of Aerosolized Bacillus anthracis Infection in BALB/c Mice and Cynomolgus Macaques. Grossman TH; Anderson MS; Drabek L; Gooldy M; Heine HS; Henning LN; Lin W; Newman JV; Nevarez R; Siefkas-Patterson K; Radcliff AK; Sutcliffe JA Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28784679 [TBL] [Abstract][Full Text] [Related]
7. Omadacycline is active Heine HS; Drusano G; Purcell BK; Anastasiou D; Tanaka SK; Serio AW Antimicrob Agents Chemother; 2024 Sep; 68(9):e0059524. PubMed ID: 39133023 [No Abstract] [Full Text] [Related]
8. Pharmacokinetic considerations and efficacy of levofloxacin in an inhalational anthrax (postexposure) rhesus monkey model. Kao LM; Bush K; Barnewall R; Estep J; Thalacker FW; Olson PH; Drusano GL; Minton N; Chien S; Hemeryck A; Kelley MF Antimicrob Agents Chemother; 2006 Nov; 50(11):3535-42. PubMed ID: 17065619 [TBL] [Abstract][Full Text] [Related]
9. Use of an in vitro pharmacodynamic model to derive a linezolid regimen that optimizes bacterial kill and prevents emergence of resistance in Bacillus anthracis. Louie A; Heine HS; Kim K; Brown DL; VanScoy B; Liu W; Kinzig-Schippers M; Sörgel F; Drusano GL Antimicrob Agents Chemother; 2008 Jul; 52(7):2486-96. PubMed ID: 18458134 [TBL] [Abstract][Full Text] [Related]
10. Evaluation of Combination Drug Therapy for Treatment of Antibiotic-Resistant Inhalation Anthrax in a Murine Model. Heine HS; Shadomy SV; Boyer AE; Chuvala L; Riggins R; Kesterson A; Myrick J; Craig J; Candela MG; Barr JR; Hendricks K; Bower WA; Walke H; Drusano GL Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28696235 [No Abstract] [Full Text] [Related]
12. Effective antimicrobial regimens for use in humans for therapy of Bacillus anthracis infections and postexposure prophylaxis. Deziel MR; Heine H; Louie A; Kao M; Byrne WR; Basset J; Miller L; Bush K; Kelly M; Drusano GL Antimicrob Agents Chemother; 2005 Dec; 49(12):5099-106. PubMed ID: 16304178 [TBL] [Abstract][Full Text] [Related]
13. Post-exposure therapy of inhalational anthrax in the common marmoset. Nelson M; Stagg AJ; Stevens DJ; Brown MA; Pearce PC; Simpson AJ; Lever MS Int J Antimicrob Agents; 2011 Jul; 38(1):60-4. PubMed ID: 21530184 [TBL] [Abstract][Full Text] [Related]